Patent · US Active

Nucleic acids encoding FGF21-Fc fusion proteins

US11129874B2 · kind B2 · utility

1Cited by

3References

12Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Brian R. Boettcher · Winchester, US
Shari Lynn Caplan · Lunenburg, US
Douglas S. Daniels · Arlington, US
Norio Hamamatsu · Belmont, US
Stuart Licht · Cambridge, US
Stephen Craig Weldon · Leominster, US

Key dates

Filing date	Aug 30, 2018
Grant date	Sep 28, 2021
Priority date	—
Expiry date	Oct 26, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to nucleic acids encoding fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are vectors and host cells comprising the same and methods of producing the fusion proteins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.